PubRank

N Manolios

Author PubWeight™ 29.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997 1.71
2 Transmembrane helical interactions: zeta chain dimerization and functional association with the T cell antigen receptor. EMBO J 1992 1.31
3 New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J 2012 1.29
4 Assessing cognitive function in rheumatoid arthritis: comment on the article by Shin et al. Arthritis Care Res (Hoboken) 2013 1.07
5 Clopidogrel-associated acute arthritis. Intern Med J 2003 0.98
6 Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 2001 0.98
7 Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 1999 0.95
8 CCR5 genotyping in an Australian and New Zealand type 1 diabetes cohort. Autoimmunity 2002 0.95
9 Structural mutations in the constant region of the T-cell antigen receptor (TCR)beta chain and their effect on TCR alpha and beta chain interaction. Immunology 1996 0.95
10 Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999 0.93
11 Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3. Eur J Immunol 1991 0.89
12 Family and twin studies in systemic lupus erythematosus. Dis Markers 1997 0.88
13 The interchain disulfide linkage of T-cell antigen receptor-alpha and -beta chains is a prerequisite for T-cell activation. Cell Immunol 1998 0.87
14 Evaluation of the apo-1/Fas promoter mva I polymorphism in multiple sclerosis. Mult Scler 2000 0.85
15 Investigation of the -1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology 2000 0.84
16 X-chromosome inactivation in monozygotic twins with systemic lupus erythematosus. Autoimmunity 1997 0.83
17 Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice. Intern Med J 2009 0.83
18 Failure to detect Bartonella henselae infection in synovial fluid from sufferers of chronic arthritis. Rheumatol Int 2000 0.82
19 Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma. Clin Rheumatol 2006 0.81
20 Herniation pit of the femoral neck. J Rheumatol 2000 0.81
21 Acute gross painless transudative ascites in a patient with lupus. BMJ Case Rep 2014 0.80
22 Evaluation of the BCL-2 gene locus as a susceptibility locus linked to the clinical expression of systemic lupus erythematosus (SLE). Rheumatol Int 1996 0.80
23 Secondary screening for osteoporosis in patients admitted with minimal-trauma fracture to a major teaching hospital. Intern Med J 2003 0.79
24 Systemic scleroderma: a spatiotemporal clustering. Intern Med J 2005 0.79
25 P2X7 gene polymorphisms do not appear to be a susceptibility gene locus in sporadic cases of systemic lupus erythematosus. Tissue Antigens 2008 0.78
26 Histiocytosis and bone: experience from one major Sydney teaching hospital. Intern Med J 2005 0.78
27 Current concepts in the etiopathogenesis and treatment of systemic lupus erythematosus (SLE). Aust N Z J Med 1986 0.78
28 Navigating motherhood choices in the context of rheumatoid arthritis: women's stories. Musculoskeletal Care 2012 0.78
29 Discrepancy in CD3-transmembrane peptide activity between in vitro and in vivo T-cell inhibition. Scand J Immunol 2006 0.78
30 Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 2005 0.77
31 Antitopoisomerase antibody positivity predates nailfold capillaroscopy abnormalities in scleroderma. Postulated classification of 'prescleroderma'. Intern Med J 2011 0.77
32 A family study of allergy: segregation with HLA but not with T-cell receptor genes. J Allergy Clin Immunol 1996 0.76
33 Resolution of sclerodermatous myocarditis after autologous stem cell transplantation. Ann Rheum Dis 2006 0.76
34 The use of biologics in the treatment of rheumatoid arthritis (RA) Aust N Z J Med 1997 0.75
35 Lymphocyte migration patterns in autoimmune MRL-lpr/lpr mice: relationship to age, disease manifestations and lymphocyte homing receptor expression. Autoimmunity 1989 0.75
36 Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and function. Intern Med J 2008 0.75
37 Glucosamine. A nutraceutical in osteoarthritis. Aust Fam Physician 2002 0.75
38 Elevated serum eosinophilic cationic protein (ECP) and expression of pemphigus-like antibodies in a case of eosinophilic fasciitis. Clin Exp Rheumatol 1997 0.75
39 Role of T-cell antigen receptors in rheumatic disease. Aust N Z J Med 1993 0.75
40 Chemotherapeutic induced fascial oedema. Ann Rheum Dis 2005 0.75
41 A Fas promoter polymorphism at position -670 in the enhancer region does not confer susceptibility to Felty's and large granular lymphocyte syndromes. Rheumatology (Oxford) 1999 0.75
42 Relationship of tumour necrosis factor alpha gene polymorphisms and neuropsychiatric lupus. Lupus 2002 0.75
43 Raynaud's phenomenon. A practical approach to a common problem. Aust Fam Physician 1993 0.75
44 Lack of linkage between anti-nuclear antibody or clinical features of systemic lupus erythematosus (SLE) and TCR-A/Vbeta loci in families of subjects with SLE. Lupus 1997 0.75
45 Familial scleroderma: nature, nurture or both? Intern Med J 2008 0.75
46 Hypothesis: lymphocyte trafficking in inflammatory rheumatic disease. A role for receptor mediated homing. J Rheumatol 1987 0.75
47 Conformation of the T-cell antigen receptor-beta chain C-domain contributes to V beta 3 epitope recognition by monoclonal antibody KJ25. Scand J Immunol 1996 0.75
48 Renal disease and rheumatic manifestations. Curr Opin Rheumatol 1994 0.75
49 [Action of T-cell antigen receptors in rheumatic diseases]. Zhonghua Nei Ke Za Zhi 1994 0.75
50 Polymyalgia rheumatica. Aust Fam Physician 1986 0.75
51 Charles bonnet syndrome in giant cell arteritis. J Clin Rheumatol 1998 0.75